There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Cogent Biosciences (COGT – Research Report) and Insulet (PODD – Research Report) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $115.00. The company’s shares closed last Thursday at $89.97.
According to TipRanks.com, Purohit is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $107.33, representing a 20.2% upside. In a report issued on February 16, Jefferies also maintained a Buy rating on the stock with a $133.00 price target.
See today’s best-performing stocks on TipRanks >>
Cogent Biosciences (COGT)
Citi analyst David Lebovitz maintained a Buy rating on Cogent Biosciences yesterday and set a price target of $11.00. The company’s shares closed last Thursday at $8.95.
According to TipRanks.com, Lebovitz is a 2-star analyst with an average return of
Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $14.25, a 68.4% upside from current levels. In a report issued on February 12, Needham also maintained a Buy rating on the stock with a $15.00 price target.
Insulet (PODD)
In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Insulet, with a price target of $260.00. The company’s shares closed last Thursday at $197.14.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insulet with a $238.90 average price target, a 23.8% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $240.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
- BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
- BMRN Earnings this Week: How Will it Perform?
- Elliott Management bought BioMarin and Etsy during Q4, exited Arm
- BioMarin to present positive data on Roctavian durability at EAHAD Congress
- BioMarin reports Jeffrey Ajer to step down as Chief Commercial Officer
